Mandalay Resources Corporation's Cerro Bayo Mine Gives Notice of Force Majeure
TORONTO, June 30, 2017 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" of the "Company") (TSX:MND) announced today that Compañia Minera Cerro Bayo, a subsidiary of the Company, has commenced giving notice of force majeure to the primary customers, suppliers and contractors of its Cerro Bayo mine. This notice suspends Cerro Bayo's obligations under contracts with these parties due to the flooding of the Delia NW mine on June 9, 2017. Mandalay is also initiating consultations with its unions about the potential impacts on employees during this period of suspended production.
Mandalay has initiated an independent technical investigation into the flooding of the Delia NW mine, as well as risk assessments for restarting operations of the Coyita, Delia SE, Marcela and Raul mines, which form the basis for Cerro Bayo's current life of mine plan. The Company is reviewing several alternatives for the future of mining at Cerro Bayo and is consulting with all stakeholders in this review process, including employees, unions, and government officials. The Company expects to be in a position to provide a more detailed update on its plans for Cerro Bayo and the impact of the suspension of operations on the Company's 2017 production guidance in conjunction with its disclosure of second quarter 2017 financial results, which is currently expected to occur after market close on August 10, 2017.
About Mandalay Resources Corporation:
Mandalay Resources is a Canadian-based natural resource company with producing assets in Australia, Chile, and Sweden, and a development project in Chile. The Company is focused on executing a roll-up strategy, creating critical mass by aggregating advanced or in-production gold, copper, silver and antimony projects in Australia, the Americas, and Europe to generate near-term cash flow and shareholder value.
This news release contains "forward-looking statements" within the meaning of applicable securities laws, including statements regarding the Company's production of gold, silver and antimony for the 2017 fiscal year. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, changes in commodity prices and general market and economic conditions. The factors identified above are not intended to represent a complete list of the factors that could affect Mandalay. A description of additional risks that could result in actual results and developments differing from those contemplated by forward-looking statements in this news release can be found under the heading "Risk Factors" in Mandalay's annual information form dated March 31, 2017, a copy of which is available under Mandalay's profile at www.sedar.com. In addition, there can be no assurance that any inferred resources that are discovered as a result of additional drilling will ever be upgraded to proven or probable reserves. Although Mandalay has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
For Further Information: Mark Sander President and Chief Executive Officer Greg DiTomaso Director of Investor Relations Contact: +1.647.260.1566
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Mandalay Resources Corporation via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Leading Medical Organizations Update Guideline for Molecular Testing and Targeted Therapies in Lung Cancer23.1.2018 21:11 | Pressmeddelande
DENVER, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer, the most common cause of cancer death worldwide. To ensure that clinicians stay apace and provide optimal patient care, three leading medical societies-the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP)-have updated their 2013 evidence-based guideline. Published today in early online release, the "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors," continues to set standards for the molecular analysis of lung cancers for test results that effectively guide targeted therapy and treatment. Targeted cancer therapies are drugs or other treatments that block the spread of cancer by interfering with specific molec
CashBet Seeks $40 Million for World's Only Complete Crypto-Ready Mobile iGaming Platform23.1.2018 16:31 | Pressmeddelande
Gaming and cryptocurrency industry leaders develop blockchain-based iGaming platform improving trust, speed, access, costs, and content availability OAKLAND, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Leading mobile-first iGaming platform provider CashBet (https://coin.cashbet.com/) today announced it seeks to raise $40 million through an Initial Coin Offering (ICO) to develop the world's first complete crypto-ready mobile iGaming platform. Interactive gaming, which includes real money, social, skill-based, esports and sports betting, hit $91 billion in 2016, led by mobile gaming. Despite strong growth, current iGaming operations continue to face three major issues: trust, speed, and cost. CashBet is the first and only vertically integrated iGaming solution to leverage blockchain technology for transparent operations, increased speed, and lower transaction fees. The CashBet Coin will be available in pre-sale starting January 24, 2018 at 5:00 p.m. GMT, with a 20 percent discount offered.
BrandSafway Announces Acquisition of Venko Groep BV23.1.2018 16:30 | Pressmeddelande
Combined customers to benefit from broader range of services and greater depth of expertise KENNESAW, GA, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has acquired Venko Groep BV, a portfolio company of Mentha Capital, effective January 1, 2018. Moving forward, the company will operate as Venko, A BrandSafway Company and become a part of Brand Energy & Infrastructure Services (Brand) in Europe. "We're excited to announce the closing of the acquisition of Venko," said Dave Witsken, President of Energy and Industrial for BrandSafway. "Venko is a leading offshore coatings maintenance provider for platforms in Europe. By leveraging the highly specialized knowledge and capabilities of Venko, we will be able to provide expanded coatings services to Brand's European customers. At the same time, with our support, Venko will now be able to offer their customers a broader inventory of access equipment and additional industrial services, such as insulation an
Data on Novel Humanized Models for Targeted Immunotherapy Development, a CrownBio Conference Talk on January 24th, 201823.1.2018 14:53 | Pressmeddelande
SAN DIEGO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will unveil data supporting use of its cost-effective, humanized drug target models at the Tumor Models Conference in San Francisco tomorrow, Wednesday, January 24th, 2018. Humanized research tools are crucial to the development of target-specific immunotherapies like pembrolizumab and ipilimumab. To help improve research in this burgeoning field, CrownBio has developed a humanized platform that informs the preclinical pharmacology of targeted immunotherapies, including solutions for PD-1, PD-L1, OX40, and CD3E. Constituent models feature fully functional murine immunity with humanized drug targets that can be used in conjunction with syngeneic tumor cell lines engineered to expr
Music Legend Joey Fatone Will Be Celebrity Grand Marshal Of First Ever 15th Annual World's Shortest St. Patrick's Day Parade In Hot Springs, Arkansas23.1.2018 13:56 | Pressmeddelande
HOT SPRINGS NATIONAL PARK, Ark., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Music legend Joey Fatone, who soared to worldwide fame as a member of boy-band *NSYNC, will be celebrity grand marshal of the First Ever 15th Annual World's Shortest St. Patrick's Day Parade in downtown Hot Springs March 17, 2018, reports Hot Springs Convention & Visitors Bureau. He'll round out a quartet of celebrities who will be part of the quirky parade, which annually draws throngs to world-famous Bridge Street, the shortest street in the world in everyday use - 98 feet long. Jon Heder, who became famous as Napoleon Dynamite, will be the parade's official starter. The 2018 parade will begin at 7:30 p.m., an hour later than previous years. The start time was changed to allow Oaklawn racing fans plenty of time to enjoy the live racing including The Rebel Stakes at Oaklawn Park, and still get downtown for the start of the parade. Morris Day and the Time will perform a free concert at the conclusion of the parade. On F
HemCheck och Region Västmanland i studie om hemolyserade blodgasprov23.1.2018 13:30 | Pressmeddelande
PRESSMEDDELANDE HemCheck och Region Västmanland i studie om hemolyserade blodgasprov Karlstad 23 januari 2018: HemCheck Sweden AB meddelar idag att bolaget tecknat ett avtal med Region Västmanland avseende en studie för att kartlägga förekomsten av hemolys i blodgasprover tagna vid akutmottagningen på Västmanlands Sjukhus i Västerås. Blodgasanalys är ett blodprov som tas rutinmässigt på sjukhus och som är ett centralt verktyg när snabba svar krävs för kritiska diagnoser. Blodgasanalysen påverkas, liksom vanlig blodprovstagning, av hemolys, men i vilken omfattning är ännu inte lika väl dokumenterat. -Idag utförs ingen hemolyskontroll på blodgasprov. Avsikten med studien är att undersöka förekomsten av hemolys i blod som analyserats i blodgasapparater och se om det kan detekteras med hjälp av ett enkelt test. Det är glädjande att vi som ett första steg i det arbetet kan genomföra en så viktig studie ihop med Region Västmanland och Västmanlands Sjukhus Västerås. Vi ser att väl fungerande
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum